Novastan® anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 1, 1997, Pages 54-58

  Lewis, B E ^a,b   Grassman, E D ^a   Wrona, L ^a   Rangel, Y ^a  

^a Diamond Inpatient Headache Unit   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

argatroban; heparin induced thrombocytopenia

Indexed keywords

ARGATROBAN; HEPARIN; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY BYPASS GRAFT; KIDNEY; PEROPERATIVE COMPLICATION; STENT;

AGED; ANTICOAGULANTS; CORONARY ARTERY BYPASS; HEPARIN; HUMANS; INTRAOPERATIVE COMPLICATIONS; KIDNEY; MALE; PIPECOLIC ACIDS; STENTS; THROMBOCYTOPENIA;

EID: 0030615270     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199701000-00009     Document Type: Article

References (29)

1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
2. Wallis DE, Lewis BE, Pifarre R, Scanlon PJ. Active surveillance for heparin-induced thrombocytopenia on thromboembolism. Chest 1994; 106: 120 (abstract).
3. Krueger SK, Andres E, Weinard E. Thrombolysis in heparin-induced thrombocytopenia with thrombosis. Ann Int Med 1985; 103: 159.
4. Lefemine AA. Complications of heparin-induced thrombocytopenia. Am Surg 1982; 48: 202-206.
5. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg 1986; 4: 522-528.
6. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with organon (ORG 10172). Thromb Haemost 1993; 70: 554-561.
7. King DE, Kelton JG. Heparin-induced thrombocytopenia. Ann Intern Med 1984; 100: 535-540.
8. Walls JT, Curtis JJ, Silver D, Boley TM. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 1990; 108: 686-693.
9. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
10. Greinacher A, Poetzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Hemost 1994; 71: 247-251.
11. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexes with heparin or heparin bound endothelial cells. J Clin Invest 1994; 93: 81-88.
12. Chong BH, Castaldi PA, Berndt M. Heparin-induced thrombo-cytopenia: effects of rabbit IgG, and FAB and FC fragments on antibody-heparin-platelet interaction. Thromb Res 1989; 55: 291-295.
13. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930.
14. Adelman B, Sobel M, Fujimura V, Ruggeri ZM, Zimmerman TS. Heparin-associated thrombocytopenia: observations on the mechanism of platelet aggregation. J Lab Clin Med 1989; 113: 204-210.
15. Hijikata A, Okamoto S. In vivo and in vitro studies of a new series of synthetic thrombin inhibitors. Thromb Res 1976; 8 (suppl): 83.
16. Kikumoto R, Tamao Y, Ohkubo K, et al. Thrombin inhibitors: 2. Amide derivatives on N alpha - substituted L-arginine. J Med Chem 1980; 23: 830-836.
17. Okamoto S, Hijikata A. Potent inhibition of thrombin by a newly synthesized arginine derivative No. 805. The importance of stereo structures of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446.
18. Matsuo T, Yamada T, Yamanashi T, Ryo R. Anticoagulant therapy with MD-805 of hemodialysis patients with heparin-induced thrombocytopenia. Thromb Res 1990; 58: 663-666.
19. Nagasawg H. Phase One study of synthetic antithrombin agent (MD-805). Jpn J Clin Pharm Ther 1981; 12: 359.
20. Tamao Y, Yamamoto T, Kikumoto R, et al. Effect of a selective thrombin inhibitor (MCI-9038) on fibrinolysis in vitro and in vivo. Thromb Haemost 1986; 56: 28-34.
21. Tanabe T. Clinical results of MD-805, antithrombin agent, on chronic arterial occlusion. J Clin Ther Med 1986; 2: 1645.
22. Lewis BE, Leya F, Johnson SA, et al. Improved hemodynamic, angiographic and functional results after renal artery stenting. J Inv Cardiol 1994; 6: 136-140.
23. Leroy J, Leclerc MH, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216). Semin Thromb Haemost 1985; 11: 326-329.
24. Laster J, Elfrink R, Silver D. Re-exposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 1989; 9: 677-682.
25. Walenga JM, Koza MJ, Lewis BE, Pifarre R. Relative heparin-induced thrombocytopenia potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb/Hemost 1996; 2 (suppl 1): S21-S27.
26. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992; 82: 622-629.
27. Chamberlin JR, Lewis BL, Leya FS, et al. Successful treatment of heparin associated thrombocytopenia and thrombosis using hirulog. Can J Cardiol 1995; 11: 511-514.
28. Data on file with Texas Biotechnology Corporation.
29. Dougherty KG, Marsh KC, Edelman SK, Gaos CM, Ferguson JJ, Leachman DR. Relationship between procedural activated clotting time and in-hospital post-PTCA outcome. Circulation 1990; 82: 111-189 (abstract).